Tebentafusp is a pharmacological breakthrough in the fight against a deadly disease.
Belzutifan by Merck & Co. is for the treatment of renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors.
Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.
Two injections of inclisiran a year and you can forget about high cholesterol. Novartis doesn’t lie.
Efgartigimod developed by Argenx is a strong competitor to Soliris.
The combination drug will help almost all cystic fibrosis patients.
Vosoritide by BioMarin Pharmaceutical may cure achondroplasia.